Sudarshan Pharma Industries share price today

Sudarshan Pharma Industries Ltd's share price was ₹35.84 at the close on 30 October 2026. It has been rising for 27 weeks. That is 4.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹20 and ₹42, and at that close it sat 73% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sudarshan Pharma Industries Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 3 weeks running.

Over the last 3.6 years the share price moved +473% while the NIFTY 500 moved +53%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 9 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

1 points in one quarter and profit up on a year earlier for 4 quarters in a row.

1. Revenue up on a year earlier for 6 quarters in a row (every quarter we can compare)

   In the September 2026 quarter revenue was ₹217 crore, +28.5% on a year earlier.

2. Promoters cut their stake by 1.1 points in one quarter

   From 58.9% to 57.8% in the September 2026 quarter.

3. Profit up on a year earlier for 4 quarters in a row

   In the September 2026 quarter profit was ₹8 crore, +101% on a year earlier.

For July to September 2026 (the quarter ended 30 September 2026), Sudarshan Pharma Industries reported revenue of ₹217 crore, up 28.5% from ₹169 crore a year earlier, and a profit of ₹7.78 crore, up 101.0% from ₹3.87 crore.

Sudarshan Pharma Industries results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Sudarshan Pharma Industries closed at ₹35.84 on 30 October 2026, up 32.6% from ₹27.03 a year earlier (31 October 2025) and up 341.4% over three years. Its highest weekly close since March 2023 was ₹48.80 on 10 January 2025.

Sudarshan Pharma Industries share price: then and now

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes.

171 weekly closes from 24 March 2023 to 30 October 2026.

30 Oct 2026: Sudarshan Pharma Industries closed at ₹35.84, up 14.7% on the week and down 3.8% on the month. Results for July to September 2026: Revenue up 28.5% and profit up 101.0% on a year earlier.

Sudarshan Pharma Industries has paid no dividend on the NSE since its first NSE close in our records (24 March 2023), the start of the period we checked.

Not in its latest year. Sudarshan Pharma Industries Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 1 of its last 7 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

Sudarshan Pharma Industries is on one of our India lists: Penny stocks.

Sudarshan Pharma Industries Ltd earned ₹7.8 Cr of net profit in the Sep 2026 quarter, +101.0% on the same quarter a year earlier. That is the 4th quarter in a row of profit growth. Full-year FY26 profit was ₹23.0 Cr. Over 6 years profit has grown 68.6% a year on average. That is 3.6% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹3.9 Cr. 1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹23.0 Cr (+43.8% on the year before).

Why profit moved: revenue changed +28.5% on a year earlier and the margin moved +4.0 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +60.2% and revenue +32.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Sudarshan Pharma Industries Ltd reported ₹217 Cr of revenue in the Sep 2026 quarter, +28.5% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 6 years it has grown 29.7% a year on average. The last full year, FY26, came in at ₹703 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹780 Cr.

FY26 revenue was ₹703 Cr, +39.2% on the year before.

Recent pace: the last four quarters grew +32.6% on average, against 29.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +31.9%, against +35.7% a year over the last 8 quarters (rolling over); profit over the last 12 months grew +59.7%, against +94.2% a year (rolling over).

Sudarshan Pharma Industries Ltd's operating margin was 9.5% in the Sep 2026 quarter, 4.0 percentage points higher than the same quarter a year ago. Across 7 years it has been between 3.1% and 8.0%. The latest quarter is above every full year in that period.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +4.0 percentage points on the year while gross margin changed +5.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

Over the last 3 years Sudarshan Pharma Industries Ltd's operations used more cash than they brought in, so cash conversion was −56%, a gap worth watching. In FY26 its operations used ₹2.0 Cr of cash, against ₹23.0 Cr of profit. After ₹40.0 Cr of spending on assets, free cash was −₹42.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why −56% of profit came in as cash: the cash cycle got 67 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 67 days longer. The next section looks at where the cash is stuck.

Sudarshan Pharma Industries Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 139 days in FY26, up from 72 days in FY21. It spent ₹94.0 Cr on assets over the last 3 years. Customers take 121 days to pay, and stock sits for 129 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹703 Cr, each day of that cycle ties up about ₹1.9 Cr, so roughly ₹268 Cr is tied up in the business at any time.

FY26: customers took 121 days to pay and stock sat for 129 days, about 4.2 months of sales sitting as stock, for a full cycle of 139 days, longer than FY21's 72.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 129 days. Customers pay about 121 days after that. Suppliers are paid at 111 days. Together that makes the 139-day cycle.

Spending on assets: ₹94.0 Cr over the last 3 years, against ₹7.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Sudarshan Pharma Industries Ltd's P/E is 31.9×, in the middle of its own history: higher than 50% of past readings. Its usual P/E (the middle reading) is 32.1×, over 3.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹1.18.

Why the multiple is where it is: over the past year earnings per share moved +47.0% while the price moved +32.6%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved +64.0% a year; about +56.0% a year came from earnings growth and about +8.0 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Sudarshan Pharma Industries Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Sudarshan Pharma Industries Ltd earned a ROCE of 15% in FY26. That is up from a low of 14% in FY24. Its return on capital used (ROIC) is 2.8 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a 3.3% net margin and 1.10× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a 3.3% net margin × 1.10× asset turnover × 4.14× leverage (assets divided by equity) ≈ 15.0% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 9.2% − 12.0% = −2.8 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

Sudarshan Pharma Industries Ltd has total debt of ₹392 Cr against shareholder equity of ₹196 Cr as of Sep 2026, so its debt is 2.00× its equity. Year by year, that ratio went from 0.74 in FY19 to 1.83 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Foreign institutions raised their stake in Sudarshan Pharma Industries Ltd by 8.9 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 21.9% of the company. Promoters moved +0.4 points over the same period, to 57.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Why the owners changed: foreign institutions drove it (+8.9 points). They raised their stake step by step.

For Sudarshan Pharma Industries Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

58.6 out of 100, rank 12 of 63 in Trading, with 85% of the evidence available.

Sudarshan Pharma Industries Ltd scores 58.6 out of 100 against the 63 companies it is compared with in Trading, ranking 12. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 22.4 + 13.8 + 11.2 + 11.2 = 58.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Sudarshan Pharma Industries ranks 12 of 63 Trading companies on the 4-Factor Sector Score, with 58.6 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Trading, all 63 compared on one page.

Sudarshan Pharma Industries is the 28th largest of 59 Trading companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Patel Retail, Aptus Pharma and Vision Infra Equipment Solutions. Just below it: Shiv Aum Steels, Prostarm Info Systems and Maxgrow India.

Trading companies close in size

25. Patel Retail Ltd ₹799 crore
26. Aptus Pharma Ltd ₹793 crore
27. Vision Infra Equipment Solutions Ltd ₹782 crore
28. Sudarshan Pharma Industries Ltd ₹780 crore
29. Shiv Aum Steels Ltd ₹742 crore
30. Prostarm Info Systems Ltd ₹735 crore
31. Maxgrow India Ltd ₹709 crore

All 59 Trading companies, largest first

Companies close in size in other industries

1748. Amines & Plasticizers Ltd ₹782 crore · Speciality Chemicals
1749. Vision Infra Equipment Solutions Ltd ₹782 crore · Trading
1750. Sudarshan Pharma Industries Ltd ₹780 crore
1751. Dhampur Bio Organics Ltd ₹779 crore · Sugar
1752. Namo eWaste Management Ltd ₹778 crore · Recycling

Sector Alpha, written by code from the published numbers. Data as of 30 October 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.